Basic Information
Pyrukynd
Regulatory Information
EMEA/H/C/005540
November 9, 2022
September 15, 2022
December 5, 2022
Company Information
Agios Netherlands B.V.,Zuidplein 36,1077XV Amsterdam,Netherlands
Netherlands
Zuidplein 36 1077XV Amsterdam
agios netherlands b.v.
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.4).
Overview Summary
Pyrukynd is a medicine used to treat adults with pyruvate kinase deficiency (PKD), an inherited disease that causes red blood cells to break down faster than normal. PKD is rare, and Pyrukynd was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 22 April 2020. Further information on the orphan designation can be found here: [https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2270](/en/medicines/human/orphan-designations/eu-3-20-2270). Pyrukynd contains the active substance mitapivat.